Reduced capacity of antibodies from patients infected with human immunodeficiency virus type 1 (HIV-1) group O to neutralize primary isolates of HIV-1 group M viruses

J Infect Dis. 1995 Nov;172(5):1228-37. doi: 10.1093/infdis/172.5.1228.

Abstract

Neutralizing antibody patterns in sera of persons infected with human immunodeficiency virus type 1 (HIV-1) groups M and O to their homologous and heterologous primary isolates were determined in a peripheral blood mononuclear cell-based neutralization assay and correlated with their ability to bind to V3 loop synthetic peptides. Most HIV-1 group M sera (9/16) neutralized HIV-1 group O viruses, whereas fewer group O sera (3/13) only weakly neutralized HIV-1 group M viruses. Group M sera neutralizing HIV-1 group O viruses neutralized other HIV-1 group M viruses with titers of 1:10-1:1280. V3 loop binding capacity of sera did not reflect their neutralizing capacity of the homologous isolate. Despite the reduced neutralizing capacity of group O-infected patients' sera to group M viruses, some group M-infected patients' sera neutralized both HIV-1 group M and O isolates, suggesting that they share some conserved neutralizing epitopes.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acquired Immunodeficiency Syndrome / blood
  • Acquired Immunodeficiency Syndrome / immunology*
  • Amino Acid Sequence
  • Blotting, Western
  • Enzyme-Linked Immunosorbent Assay
  • Epitopes / chemistry
  • Epitopes / immunology*
  • Gene Products, env / genetics
  • Gene Products, env / immunology*
  • Genes, env
  • Genes, gag
  • HIV Antibodies / blood
  • HIV Antibodies / immunology*
  • HIV-1 / classification*
  • HIV-1 / immunology*
  • HIV-1 / isolation & purification
  • Humans
  • Lymphocytes / immunology*
  • Lymphocytes / virology
  • Molecular Sequence Data
  • Neutralization Tests
  • Peptide Fragments / chemical synthesis
  • Peptide Fragments / chemistry
  • Peptide Fragments / immunology
  • Phylogeny

Substances

  • Epitopes
  • Gene Products, env
  • HIV Antibodies
  • Peptide Fragments